Meeder Asset Management’s Gilead Sciences GILD Stock Holding History

Meeder Asset Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.5M	Sell	147,283 -3,657	-2%	-$512K	1.18%	18
2025 Q4	$18.5M	Sell	150,940 -5	-0%	-$608	1%	22
2025 Q3	$16.8M	Sell	150,945 -17,129	-10%	-$1.95M	0.96%	26
2025 Q2	$18.6M	Buy	168,074 +47	+0%	+$5K	1.14%	18
2025 Q1	$18.8M	Sell	168,027 -46,579	-22%	-$4.81M	1.27%	16
2024 Q4	$19.8M	Buy	214,606 +24,571	+13%	+$2.21M	1.38%	18
2024 Q3	$15.9M	Buy	190,035 +42,444	+29%	+$3.24M	1.06%	23
2024 Q2	$10.1M	Buy	147,591 +72,283	+96%	+$4.82M	0.71%	31
2024 Q1	$5.52M	Sell	75,308 -18,704	-20%	-$1.44M	0.35%	66
2023 Q4	$7.62M	Buy	+94,012	New	+$7.32M	0.59%	44
2023 Q3	–	Sell	-95,376	Closed	-$7.35M	–	527
2023 Q2	$7.35M	Buy	95,376 +2,614	+3%	+$208K	0.53%	45
2023 Q1	$7.7M	Buy	92,762 +364	+0.4%	+$30.1K	0.61%	39
2022 Q4	$7.93M	Sell	92,398 -26,642	-22%	-$2.11M	0.69%	27
2022 Q3	$7.34M	Buy	119,040 +7,628	+7%	+$481K	0.42%	50
2022 Q2	$6.89M	Buy	111,412 +3,113	+3%	+$193K	0.4%	52
2022 Q1	$6.44M	Buy	+108,299	New	+$6.92M	0.31%	65
2021 Q4	–	Sell	-87,930	Closed	-$6.14M	–	1629
2021 Q3	$6.14M	Buy	87,930 +2,255	+3%	+$158K	0.32%	77
2021 Q2	$5.9M	Buy	85,675 +393	+0.5%	+$26.2K	0.28%	80
2021 Q1	$5.51M	Buy	85,282 +73,048	+597%	+$4.71M	0.28%	78
2020 Q4	$713K	Sell	12,234 -69,646	-85%	-$4.2M	0.16%	118
2020 Q3	$5.17M	Sell	81,880 -2,629	-3%	-$182K	0.33%	67
2020 Q2	$6.5M	Sell	84,509 -34,120	-29%	-$2.61M	0.42%	54
2020 Q1	$8.87M	Sell	118,629 -50,242	-30%	-$3.47M	0.69%	26
2019 Q4	$11M	Buy	168,871 +40,104	+31%	+$2.61M	0.67%	33
2019 Q3	$8.16M	Buy	128,767 +23,220	+22%	+$1.52M	0.54%	60
2019 Q2	$7.13M	Buy	105,547 +12,697	+14%	+$835K	0.5%	62
2019 Q1	$6.04M	Buy	92,850 +2,671	+3%	+$178K	0.48%	63
2018 Q4	$5.64M	Sell	90,179 -9,891	-10%	-$691K	0.5%	54
2018 Q3	$7.73M	Buy	100,070 +5,841	+6%	+$441K	0.58%	49
2018 Q2	$6.68M	Buy	94,229 +22,843	+32%	+$1.61M	0.58%	46
2018 Q1	$5.38M	Sell	71,386 -4,790	-6%	-$381K	0.5%	49
2017 Q4	$5.46M	Buy	76,176 +4,884	+7%	+$371K	0.46%	48
2017 Q3	$5.78M	Sell	71,292 -22,217	-24%	-$1.7M	0.63%	29
2017 Q2	$6.62M	Buy	93,509 +9,221	+11%	+$614K	0.63%	30
2017 Q1	$5.72M	Buy	84,288 +4,632	+6%	+$326K	0.51%	47
2016 Q4	$5.7M	Buy	79,656 +17,122	+27%	+$1.27M	0.55%	46
2016 Q3	$4.95M	Buy	62,534 +24,250	+63%	+$1.97M	0.42%	41
2016 Q2	$3.19M	Sell	38,284 -10,563	-22%	-$937K	0.3%	62
2016 Q1	$4.49M	Sell	48,847 -15,390	-24%	-$1.39M	0.42%	43
2015 Q4	$6.5M	Sell	64,237 -16,416	-20%	-$1.71M	0.59%	33
2015 Q3	$7.92M	Sell	80,653 -4,642	-5%	-$516K	0.78%	14
2015 Q2	$9.99M	Buy	85,295 +3,585	+4%	+$392K	1.01%	15
2015 Q1	$8.02M	Sell	81,710 -10,000	-11%	-$1.02M	0.86%	17
2014 Q4	$8.64M	Buy	91,710 +250	+0.3%	+$25.9K	1.1%	12
2014 Q3	$9.74M	Buy	91,460 +27,755	+44%	+$2.72M	1.43%	6
2014 Q2	$5.28M	Buy	+63,705	New	+$4.96M	0.78%	36

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Meeder Asset Management's GILD Position: Q1 2026 in Review

Meeder Asset Management reduced its Gilead Sciences (GILD) stake by 2.4% in Q1 2026, selling an estimated $512K and leaving 147,283 shares worth $20.5M. The position accounts for 1.18% of the portfolio, ranked #18.

Meeder Asset Management first reported a position in GILD in Q2 2014 and has held it in 46 quarters since. 2,312 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Meeder Asset Management held 147,283 shares of Gilead Sciences worth $20.5M as of Q1 2026.
Meeder Asset Management sold 3,657 Gilead Sciences shares in Q1 2026, an estimated $512K.
Gilead Sciences made up 1.18% of Meeder Asset Management's portfolio in Q1 2026, its #18 holding.
Meeder Asset Management first reported a position in Gilead Sciences in Q2 2014 and has held it in 46 quarters since.
2,312 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.